Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00670410 · ClinicalTrials.gov registry record · Phase 1
Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma
A Phase 1 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00670410 is a Phase 1 study that was terminated before completion, run by Columbia University. The registered enrollment target is 15 participants.
The verdict
NCT00670410, a Phase 1 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
Neuroblastoma is a malignant tumor of the sympathetic nervous system. It is the second most common malignant tumor of childhood. Although modest advances have been made over the past 20 years children with high-risk neuroblastoma continue to have an unsatisfactory long-term survival. This study will administer induction chemotherapy followed by high-dose (myeloablative) chemotherapy with autologous stem cell transplantation, followed by radiation therapy, then immunotherapy with a non myeloablative allogeneic stem cell transplant for treatment of neuroblastoma. The purpose of this clinical research trial is to study the feasibility of giving immunotherapy with a non-myeloablative allogeneic transplant (NAT/AlloSCT), following myeloablative therapy and autologous stem cell transplant (MAT/AutoSCT). This study will also determine the side effects as well as the response rate for each group of patients (treatment arm).
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- DRUG Thymoglobulin
- PROCEDURE Related donor transplant
- PROCEDURE Cord blood transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2003-11 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00670410
The ClinicalTrials.gov registry entry for NCT00670410 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT00670410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00670410 about?
NCT00670410 is a clinical study titled "Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma". Neuroblastoma is a malignant tumor of the sympathetic nervous system. It is the second most common malignant tumor of childhood. Although modest advances have been made over the past 20 years children with high-risk neuroblastoma continue to have an unsatisfactory long-term survival. This study will...
What is the current status of trial NCT00670410?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2003-11. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00670410?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Thymoglobulin (DRUG), Related donor transplant (PROCEDURE), Cord blood transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00670410?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.